Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN Vaccine for Mpox in Adolescents and Adults
NCT05740982Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of JYNNEOS in mpox, sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2023; status: completed.
02
Drugs
JYNNEOS
03
Conditions
mpox
Beyond the preview
Go deeper on NCT05740982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740982.